Clinical Trial Update: A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism [Phase 2]

View source ↗

Summary

TAK-448 was evaluated in a Phase 2a pharmacodynamic study for Hypogonadotropic Hypogonadism, but the trial was terminated and results were posted in March 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropic Hypogonadism

Drugs mentioned

• TAK-448

Snippet

Sponsor: Takeda | Conditions: Hypogonadotropic Hypogonadism | Phase 2 | Status: TERMINATED | Results posted: 2017-03-31